UniQure N.V., a Dutch biotech company, is working tirelessly to develop innovative treatments for rare and devastating diseases. Among its promising offerings is HEMGENIX, which recently completed its Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company is also making strides with its gene therapy AMT-130, currently in a Phase I/II clinical study aimed at treating Huntington's disease. In addition, UniQure N.V. has several other promising treatments in the works, including AMT-162 for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis, AMT-260 for temporal lobe epilepsy, AMT-191 for fabry disease, AMT-161 for amyotrophic lateral sclerosis caused by mutations, AMT-240 for autosomal dominant Alzheimer's disease, and AMT-210 for Parkinson's disease. Founded in 1998, UniQure N.V. is based in Amsterdam, the Netherlands.
uniQure's ticker is QURE
The company's shares trade on the NASDAQ stock exchange
They are based in Amsterdam, Netherlands
There are 201-500 employees working at uniQure
It is uniqure.com/index.php
uniQure is in the Healthcare sector
uniQure is in the Biotechnology industry
The following five companies are uniQure's industry peers: